AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01486667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
Study NCT00672243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + sirolimus
Description: Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
Study NCT03295747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
Study NCT03224156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
Study NCT02858713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene + Betamethasone Dipropionate
Description: Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
Study NCT01734356 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Study NCT03474770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIS-001ER
Description: BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Study NCT02858713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App
Description: App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
Study NCT02337660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: One ultrasound guided liver biopsy
Study NCT02337660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic clamp
Description: I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
Study NCT00629707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous fluid treatment
Description: infusion of intravenous fluids (0.9% saline and 0.45% saline)
Study NCT01277250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation program
Description: Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay.
Study NCT01277250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based smoking cessation program
Description: Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay.
Study NCT03344588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: artery preserving varicocelectomy
Description: During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
Study NCT03344588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: artery ligation varicocelectomy
Description: During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
Study NCT01837238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
Study NCT01837238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group will consume non-nutritive placebo pills daily for 6 months.
Study NCT01331044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Nut
Description: to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
Study NCT01331044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Khichuri and Halwa
Description: Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day
Study NCT02566902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Piece Nebulizer
Description: Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
Study NCT02566902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-Enhanced Nebulizer
Description: Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
Study NCT02566902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
Study NCT02566902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
Study NCT02566902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
Study NCT02566902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
Study NCT02566902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
Study NCT02566902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
Study NCT03879460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: 50 mg per os naltrexone hydrochloride
Study NCT01723176 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Study NCT04426292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological testing
Description: Antibody testing for Sars-COV-2 antibodies in blood.
Study NCT03967847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral Ketorolac
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Asenapine
Description: Asenapine prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Description: Aripiprazole prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Quetiapine
Description: Quetiapine prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Risperidone prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Olanzapine
Description: Olanzapine prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Ziprasidone
Description: Ziprasidone prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Iloperidone
Description: Iloperidone prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Paliperidone
Description: Paliperidone prescribed as recorded in the CPRD in the UK
Study NCT03924089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement with probiotics
Description: Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
Study NCT03924089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement without probiotics
Description: Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
Study NCT03924089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations
Study NCT02041156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic and resistance training
Study NCT02041156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic combined with balance training
Study NCT02212613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
Study NCT01231399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01231399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01231399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01231399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study NCT01231399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01231399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01231399 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT02808156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral upper limbs intensive training
Description: The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
Study NCT02808156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bilateral upper limbs intensive training
Description: The bimanual intensive training focuses activities that required the use of both hands.
Study NCT01136967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study NCT02562339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
Study NCT04428216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group RIB
Description: In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Lurasidone
Description: Lurasidone prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Clozapine
Description: Clozapine prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Amisulpride
Description: Amisulpride prescribed as recorded in the CPRD in the UK
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Sertindole
Description: Sertindole prescribed as recorded in the CPRD in the UK
Study NCT04459533 — intervention group
Intervention type: DEVICE
Intervention: TOF protocol
Description: To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If >=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1.
Study NCT02392143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Education Material
Description: The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
Study NCT02392143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Detailing
Description: Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
Study NCT02392143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Detailing+Telephone Education
Description: PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
Study NCT04271579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Lymphnode dissection
Description: A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)
Study NCT02140411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Intravitreal injections
Description: Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
Study NCT03946553 — intervention group
Intervention type: OTHER
Description: No intervention
Study NCT03357835 — intervention group
Intervention type: OTHER
Intervention: Trauma Decision System
Description: At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
Study NCT01892683 — intervention group
Intervention type: DRUG
Intervention: General anesthesia with propofol
Description: Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
Study NCT01498770 — intervention group
Intervention type: DRUG
Intervention: Zotepine
Description: Zotepine prescribed as recorded in the CPRD in the UK
Study NCT00790894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ixabepilone
Description: Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
Study NCT00790894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
Study NCT00150813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Pharmaceutical form: oral tablets Route of administration: Oral use
Study NCT03425747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
Study NCT03425747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
Study NCT01499056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell injection
Description: intra articular inection of mesenchymal stem cell
Study NCT02336971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT for PTSD
Description: CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
Study NCT02336971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
Study NCT02457260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 N Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
Study NCT03217331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD-102
Description: 14 mg CRD-102 capsules administered twice daily orally for 14 days.
Study NCT03624972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Starting the Conversation Video
Description: The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
Study NCT03624972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual and Menopausal Health Resources
Description: Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
Study NCT01332955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz
Study NCT01332955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegIFN alfa-2a
Description: Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks